Avalo Therapeutics, Inc. (NASDAQ:AVTX) Stock Has Average Target Price of $45.10 According to Brokerages

Avalo Therapeutics, Inc. (NASDAQ:AVTX) has been given an average recommendation of “Moderate Buy” by the thirteen ratings firms that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating and twelve have issued a buy rating on the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $45.10.

A number of equities research analysts have issued reports on the company. HC Wainwright reduced their price target on Avalo Therapeutics from $35.00 to $30.00 and set a “buy” rating on the stock in a research report on Friday, August 7th. Guggenheim set a $48.00 target price on shares of Avalo Therapeutics and gave the company a “buy” rating in a report on Friday, August 7th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Avalo Therapeutics in a research note on Wednesday, September 16th. Weiss Ratings upgraded shares of Avalo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Finally, BTIG Research reissued a “buy” rating and issued a $58.00 price objective on shares of Avalo Therapeutics in a research report on Tuesday, June 16th.

Insider Buying and Selling

In related news, CFO Christopher Sullivan sold 12,394 shares of the stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $16.33, for a total transaction of $202,394.02. Following the completion of the sale, the chief financial officer owned 39,900 shares in the company, valued at $651,567. This represents a 23.70% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 24,258 shares of company stock valued at $415,434. 4.46% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Renaissance Technologies LLC boosted its stake in shares of Avalo Therapeutics by 556.4% during the first quarter. Renaissance Technologies LLC now owns 120,114 shares of the company’s stock worth $1,793,000 after buying an additional 101,814 shares during the period. Seven Fleet Capital Management LP increased its position in Avalo Therapeutics by 806.0% in the 1st quarter. Seven Fleet Capital Management LP now owns 573,883 shares of the company’s stock valued at $8,568,000 after acquiring an additional 510,540 shares during the period. DV Trading LLC purchased a new stake in Avalo Therapeutics during the 1st quarter valued at approximately $5,376,000. Sei Investments Co. purchased a new stake in Avalo Therapeutics during the 1st quarter valued at approximately $849,000. Finally, Affinity Asset Advisors LLC lifted its position in Avalo Therapeutics by 27.6% during the 1st quarter. Affinity Asset Advisors LLC now owns 1,340,840 shares of the company’s stock worth $20,019,000 after acquiring an additional 289,786 shares during the period. 87.06% of the stock is currently owned by institutional investors and hedge funds.

Avalo Therapeutics Stock Down 1.6%

Shares of AVTX stock opened at $15.47 on Friday. Avalo Therapeutics has a 52 week low of $10.70 and a 52 week high of $24.27. The stock has a market capitalization of $829.66 million, a PE ratio of -3.54 and a beta of 0.78. The firm has a 50 day moving average of $18.48 and a two-hundred day moving average of $16.97.

Avalo Therapeutics (NASDAQ:AVTX) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.83) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.25). Analysts expect that Avalo Therapeutics will post -2.82 EPS for the current fiscal year.

About Avalo Therapeutics

Avalo Therapeutics, Inc is a clinical-stage biotechnology company focused on developing therapies for immune-mediated and inflammatory diseases. The company’s research strategy centers on treatments intended to address conditions in which abnormal immune system activity contributes to disease progression.

Avalo’s lead product candidate is AVTX-009, an investigational fully human monoclonal antibody designed to inhibit interleukin-1 beta (IL-1β), a signaling protein involved in inflammation.